Milton Acturus targets commodities

The Axa Framlington Biotech fund was acquired on 16 July and represents Miton’s first foray back into the biotech sector for some years. The second half of the year generally sees more activity in the biotech sector driven by inflows of clinical news data, and according to fund manager Tom McGrath: “After years of underperformance there could be plenty of M&A activity and the sector could move.” The commodity growth story influenced McGrath’s purchase of the Schroder Agricultural fund on July 4. “The growth in population and farmers’ predilection to plant for biofuel rather than ru...